RxDoctor Payments DataLook up a doctor →

Marguerite Butchee, MD

Neurology · Oklahoma City, OKNPI 1558622282

Payments from drug & device makers

$323,563in general payments, 2019–2025

Across 2,021 payments — averaging $160.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$181K
  • Pfizer$51K
  • Biohaven Pharmaceuticals, Inc.$29K
  • Lilly USA, LLC$18K
  • Amgen$15K
  • Biohaven Pharmaceutical Holding Company Ltd.$10K
  • plus $19K from 54 others

What the payments were for

  • Consulting fees$13,3474%
  • Speaking & faculty fees$259,69880%
  • Grants$1290%
  • Travel & lodging$19,1166%
  • Food & beverage$31,24910%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)598$181,279
Pfizer108$51,130
Biohaven Pharmaceuticals, Inc.81$28,535
Lilly USA, LLC67$17,827
Amgen(2 entities)73$14,838
Biohaven Pharmaceutical Holding Company Ltd.42$10,471
Impel Pharmaceuticals Inc.12$1,957
Teva Pharmaceuticals USA, Inc.138$1,729
UCB, Inc.85$1,308
Lundbeck LLC62$1,307
Novartis89$1,068
SK Life Science, Inc.43$899
Acadia Pharmaceuticals Inc61$892
AstraZeneca35$662
Supernus Pharmaceuticals, Inc.45$642
Sanofi31$623
Livanova USA, Inc.23$563
Biogen29$558
Merz Pharmaceuticals, LLC22$540
Amneal Pharmaceuticals LLC37$532
Eisai Inc.23$526
Neurocrine Biosciences, Inc.28$472
TG Therapeutics, Inc.23$447
CSL Behring19$378
Sunovion Pharmaceuticals Inc.31$373
Genentech USA, Inc.17$345
Grifols USA, LLC13$264
Argenx US, Inc.13$253
Upsher-smith Laboratories LLC11$211
MDD US Operations, LLC11$209
Alnylam Pharmaceuticals Inc.10$197
Sumitomo Pharma America, Inc.16$179
Medtronic(2 entities)4$179
Acorda Therapeutics, Inc8$160
Banner Life Sciences, LLC8$148
GE HealthCare6$147
EMD Serono, Inc.7$118
E.r. Squibb & Sons, L.L.C.8$112
Johnson & Johnson5$94
Jazz Pharmaceuticals Inc.4$89
Greenwich Biosciences, Inc.2$86
Bristol Myers Squibb6$86
Adamas Pharmaceuticals, Inc.6$82
Corium, LLC4$76
Mallinckrodt Enterprises LLC4$73
Kyowa Kirin, Inc.5$71
Catalyst Pharmaceuticals, Inc.4$61
Avanir Pharmaceuticals, Inc.4$61
Arbor Pharmaceuticals, Inc.4$58
Merz North America, Inc.3$53
Tanabe Pharma America, Inc.3$48
Promius Pharma LLC3$47
Impel Pharmaceuticals LLC3$46
ANI Pharmaceuticals, Inc.2$41
Xeris Pharmaceuticals, Inc.2$40
Axsome Therapeutics, Inc.2$37
Avion Pharmaceuticals2$34
Azurity Pharmaceuticals, Inc.2$32
Ipsen Biopharmaceuticals, Inc1$29
Scilex Pharmaceuticals Inc.2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$323,563 in reported general payments places this provider in the 90th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$422,615
Medicare patients
263
Services billed
56,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant112$168,182
Emgality PenGalcanezumab-Gnlm206$148,155
Nurtec OdtRimegepant Sulfate86$138,552
QuliptaAtogepant77$96,920
Ajovy AutoinjectorFremanezumab-Vfrm61$53,881
Aimovig AutoinjectorErenumab-Aooe58$52,594
BotoxOnabotulinumtoxina23$29,953
BriviactBrivaracetam19$29,424
AptiomEslicarbazepine Acetate17$22,328
XcopriCenobamate15$17,067
Ajovy SyringeFremanezumab-Vfrm11$13,218
VimpatLacosamide11$12,277
Emgality SyringeGalcanezumab-Gnlm12$8,590
LamictalLamotrigine11$8,308
Lacosamide111$7,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$181,279$295,055212 claims
PfizerNurtec Odt$51,130$138,55286 claims
UCB, Inc.Briviact, Vimpat$1,308$41,70130 claims
Sunovion Pharmaceuticals Inc.Aptiom$373$22,32817 claims
SK Life Science, Inc.Xcopri$899$17,06715 claims
Upsher-smith Laboratories LLCTopiramate$211$3,107158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 152 neurology providers in Oklahoma.

Other neurology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →